73042-50-9

Usage

Structure

Bicyclic heterocyclic compound derived from benzimidazole

Pharmacological Activities

Potential anti-cancer and anti-inflammatory agent

Cancer Cell Growth Inhibition

Ability to inhibit the growth of cancer cells

Inflammation Reduction

Known for reducing inflammation in the body

Research Potential

Used in research for its potential as a therapeutic agent for various diseases and conditions

Further Studies

More studies needed to understand its mechanism of action and potential applications

Upstream product

• 25810-58-6 (D,L)-2-(1-benzoylaminoethyl)benzimidazole 
• 95-54-5 1,2-diamino-benzene 
• 302-72-7 rac-Ala-OH 
• 25810-63-3 1-(1H-benzimidazol-2-yl)-ethylamine; dihydrochloride 

Downstream Products

• 1169393-57-0 (R)-N-[1-(1H-benzimidazol-2-yl)ethyl]acetamide 
• 135875-04-6 (S)-α-methyl-1H-benzimidazole-2-methanamine 
• 163959-79-3 (R)-α-methyl-1H-benzimidazole-2-methanamine 
• 74461-41-9 3-[1-(1H-Benzoimidazol-2-yl)-ethyl]-8-iodo-2-phenyl-3H-quinazolin-4-one 
• 74461-39-5 3-[1-(1H-Benzoimidazol-2-yl)-ethyl]-8-bromo-2-phenyl-3H-quinazolin-4-one 
• 73042-51-0 3-[1-(1H-benzoimidazol-2-yl)-ethyl]-2-phenyl-3H-quinazolin-4-one 
• 74461-40-8 3-[1-(1H-Benzoimidazol-2-yl)-ethyl]-6,8-dibromo-2-phenyl-3H-quinazolin-4-one 

Relevant academic research and scientific papers

Stereoselective chemoenzymatic synthesis of enantiopure 1-(Heteroaryl)ethanamines by lipase-Catalysed kinetic resolutions

The efficient chemical synthesis and enzymatic kinetic resolution of a family of 1-(heteroaryl)ethanamines have been performed with lipases responsible for the preparation of nitrogenated compounds in high optical purity. Thus, Candida antarctica lipase type B has been identified as an excellent biocatalyst for the stereoselective production of the corresponding enantiomerically enriched (B)-acetamides and (S)-amines. A similar effect of the heteroatom in the cyclic ring has been observed in terms of reactivity and enantio- selectivity, with benzoxazole, benzothiazole and benzimidazole derivatives being obtained with excellent enantiopurities after one day of reaction. Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2009.

BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS

The present invention provides compounds having formula (I) wherein n, p, q and r are each independently selected from 0 or 1; a, b, c, and d each independently represents a carbon or nitrogen atom, with the proviso that no more than two of a, b, c, and d are nitrogen atoms; Y and Y' each independently represents 1-4 optional substituents selected from alkyl, alkoxy, halo, -CF3, and -C(O)OH; R, R, R and R are H or specified substituents; R, R, R, R, R, R, R and R are independently selected from H or C1-C3 alkyl; or a biolabile ester thereof, or a pharmaceutically acceptable salt thereof. Also provided are methods of using these compounds for treating vitronectin-mediated disorders, e.g., cancer, retinopathy, artherosclerosis, vascular restenosis, and osteoporosis.

Benzimidazole compounds that are vitronectin receptor antagonists

The present invention provides compounds having the formula wherein n, p, q and r are each independently selected from 0 or 1; a, b, c, and d each independently represents a carbon or nitrogen atom, with the proviso that no more than two of a, b, c, and d

Search for non-steroidal anti-inflammatory agents. Part 1: Synthesis of 2-alkyl/aryl-3-benzimidazolylalkylquinazolon-4(3H)-ones.

Sixteen title compounds have been synthesized and some of them have shown interesting results in antiinflammatory screening against carrageenin-induced inflammation. In addition, the compounds were found to be central nervous system depressants and relatively non-toxic.